📰 Interval Prolongation News
Interval Prolongation News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Interval Prolongation. Real-time updates on events, politics, business and more.
December 9, 2023
/PRNewswire/ -- Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, will be presenting new data in acute...
October 8, 2023
Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Contingent Value Right Acquisition Brings KRAZATI® , a...
June 9, 2023
/PRNewswire/ -- Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced updated data from the...
May 10, 2023
/PRNewswire/ -- Servier, a global pharmaceutical group, today announced that the European Commission (EC) has approved Tibsovo® (ivosidenib tablets) as a...
December 10, 2022
/PRNewswire/ -- Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today presented new data at the 64th...
December 7, 2022
/PRNewswire/ -- Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, was the recipient of the Patient Champion...
June 1, 2022
Wide range of research across tumor types underscores Serviers commitment to discovering novel approaches to addressing difficult-to-treat cancers Phase 3...
May 25, 2022
/PRNewswire/ -- Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced that the U.S. Food and...
May 25, 2022
TIBSOVO is the first therapy targeting cancer metabolism approved in combination with azacitidine for patients with newly diagnosed IDH1-mutated acute myeloid leukemia FDA approval based
May 25, 2022
/PRNewswire/ -- Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced that the U.S. Food and...